Bluebird Bio Inc. (NASDAQ:BLUE) was down 2% during mid-day trading on Thursday . The company traded as low as $45.27 and last traded at $45.59, with a volume of 396,613 shares traded. The stock had previously closed at $46.52.

A number of equities research analysts have issued reports on BLUE shares. Leerink Swann reaffirmed an “outperform” rating and issued a $67.00 price objective on shares of Bluebird Bio in a research report on Tuesday, April 5th. BTIG Research reissued a “buy” rating and set a $72.00 target price on shares of Bluebird Bio in a research report on Sunday, April 3rd. Vetr downgraded shares of Bluebird Bio from a “strong-buy” rating to a “sell” rating and set a $44.44 target price for the company. in a research report on Wednesday, June 8th. Jefferies Group reissued a “buy” rating and set a $80.00 target price on shares of Bluebird Bio in a research report on Friday, July 8th. Finally, Zacks Investment Research downgraded shares of Bluebird Bio from a “hold” rating to a “sell” rating in a research report on Monday, May 9th. One investment analyst has rated the stock with a sell rating, six have issued a hold rating and twelve have given a buy rating to the company. The stock currently has an average rating of “Buy” and an average target price of $96.09.

The company’s market cap is $1.68 billion. The firm’s 50 day moving average is $43.95 and its 200-day moving average is $46.21.

Bluebird Bio (NASDAQ:BLUE) last posted its quarterly earnings data on Wednesday, May 4th. The company reported ($1.52) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($1.23) by $0.29. During the same quarter last year, the business earned ($0.76) EPS. The business had revenue of $1.50 million for the quarter, compared to analyst estimates of $4.50 million. The firm’s revenue was down 76.2% on a year-over-year basis. On average, equities analysts expect that Bluebird Bio Inc. will post ($5.90) earnings per share for the current year.

In other news, insider Philip D. Gregory sold 2,931 shares of the company’s stock in a transaction dated Thursday, June 16th. The shares were sold at an average price of $39.52, for a total value of $115,833.12. Following the transaction, the insider now directly owns 30,069 shares in the company, valued at $1,188,326.88. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, insider David Davidson sold 1,000 shares of the company’s stock in a transaction dated Wednesday, June 15th. The stock was sold at an average price of $40.11, for a total transaction of $40,110.00. Following the completion of the transaction, the insider now owns 10,600 shares in the company, valued at $425,166. The disclosure for this sale can be found here.

Several hedge funds and institutional investors recently bought and sold shares of the company. State Board of Administration of Florida Retirement System boosted its position in Bluebird Bio by 6.7% in the fourth quarter. State Board of Administration of Florida Retirement System now owns 37,859 shares of the company’s stock worth $2,431,000 after buying an additional 2,385 shares during the last quarter. Nationwide Fund Advisors boosted its position in Bluebird Bio by 40.8% in the fourth quarter. Nationwide Fund Advisors now owns 40,800 shares of the company’s stock worth $2,620,000 after buying an additional 11,830 shares during the last quarter. Rhumbline Advisers boosted its position in Bluebird Bio by 6.0% in the fourth quarter. Rhumbline Advisers now owns 35,855 shares of the company’s stock worth $2,303,000 after buying an additional 2,023 shares during the last quarter. California Public Employees Retirement System boosted its position in Bluebird Bio by 157.2% in the fourth quarter. California Public Employees Retirement System now owns 94,400 shares of the company’s stock worth $6,062,000 after buying an additional 57,700 shares during the last quarter. Finally, ProShare Advisors LLC boosted its position in Bluebird Bio by 6.5% in the fourth quarter. ProShare Advisors LLC now owns 30,869 shares of the company’s stock worth $1,982,000 after buying an additional 1,888 shares during the last quarter.

bluebird bio, Inc is a biotechnology company. The Company is focused on developing transformative gene therapies for severe genetic and rare diseases and in the field of T cell-based immunotherapy. Its gene therapy clinical programs include LentiGlobin product candidate to treat transfusion-dependent B-thalassemia (TDT) and severe sickle cell disease (SCD), and Lenti-D product candidate to treat cerebral adrenoleukodystrophy (CALD), a rare hereditary neurological disorder.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.